Praxis Precision Medicines (PRAX) News Today $31.53 -1.12 (-3.43%) Closing price 04:00 PM EasternExtended Trading$31.54 +0.02 (+0.05%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Franklin Resources Inc. Sells 55,398 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Franklin Resources Inc. lessened its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 389,835 shares of the company's stocApril 7 at 4:13 AM | marketbeat.com45,427 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Acquired by Pictet Asset Management Holding SAPictet Asset Management Holding SA acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 45,427 shares of the company's stock, valued at approximApril 6 at 3:50 AM | marketbeat.comPraxis Precision Medicines to Participate in Upcoming April ConferencesApril 3, 2025 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2025 | gurufocus.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2025 | globenewswire.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1% - What's Next?Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 5.1% - Here's WhyApril 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.1% - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 7.1% - Here's WhyMarch 27, 2025 | marketbeat.comPraxis Precision management to meet with Piper SandlerMarch 25, 2025 | markets.businessinsider.comSimplify Asset Management Inc. Buys New Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)Simplify Asset Management Inc. purchased a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,085 shares oMarch 24, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by BrokeragesPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and nine have issued a buMarch 20, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.2% - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.2% - Here's WhyMarch 19, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Short Interest Down 31.8% in FebruaryPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) saw a large decline in short interest in February. As of February 28th, there was short interest totalling 1,820,000 shares, a decline of 31.8% from the February 13th total of 2,670,000 shares. Based on an average daily volume of 459,200 shares, the short-interest ratio is currently 4.0 days. Approximately 9.7% of the shares of the stock are sold short.March 16, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Sold by Candriam S.C.A.Candriam S.C.A. decreased its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 27.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,970 shares of the company's stock afterMarch 8, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.7% - What's Next?Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.7% - Here's WhyMarch 7, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for PRAX Q1 Earnings?Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Stock analysts at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Praxis Precision Medicines in a note issued to investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will postMarch 6, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week Low on Analyst DowngradePraxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low After Analyst DowngradeMarch 5, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comPraxis Precision price target lowered to $105 from $120 at H.C. WainwrightMarch 4, 2025 | markets.businessinsider.comPraxis Precision price target lowered to $73 from $117 at BairdMarch 4, 2025 | markets.businessinsider.comPraxis: Still A 'Hold' Despite Interim Analysis Setback Of UlixacaltamideMarch 4, 2025 | seekingalpha.comPraxis Precision Medicines to Participate in Five Upcoming Investor ConferencesMarch 4, 2025 | tmcnet.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist FinancialTruist Financial dropped their price objective on Praxis Precision Medicines from $175.00 to $85.00 and set a "buy" rating on the stock in a research note on Monday.March 3, 2025 | marketbeat.comPraxis Precision price target lowered to $65 from $111 at Deutsche BankMarch 3, 2025 | markets.businessinsider.comAssessing Praxis Precision Medicine: Insights From 5 Financial AnalystsMarch 3, 2025 | benzinga.comPraxis Precision price target lowered to $85 from $150 at NeedhamMarch 3, 2025 | markets.businessinsider.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLCNeedham & Company LLC dropped their price objective on Praxis Precision Medicines from $150.00 to $85.00 and set a "buy" rating for the company in a research note on Monday.March 3, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Forecast for Praxis Precision Medicines (NASDAQ:PRAX) Stock PriceHC Wainwright cut their target price on shares of Praxis Precision Medicines from $120.00 to $105.00 and set a "buy" rating for the company in a research report on Monday.March 3, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $73.00 at Robert W. BairdRobert W. Baird dropped their price target on Praxis Precision Medicines from $117.00 to $73.00 and set an "outperform" rating for the company in a research note on Monday.March 3, 2025 | marketbeat.comPraxis Precision price target lowered to $85 from $175 at TruistMarch 1, 2025 | markets.businessinsider.comPraxis Precision Medicines (NASDAQ:PRAX) Issues Quarterly Earnings ResultsPraxis Precision Medicines (NASDAQ:PRAX - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.76) by ($0.18). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%.March 1, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings MissPraxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down on Disappointing EarningsMarch 1, 2025 | marketbeat.comPraxis Precision downgraded to Underperform at Wedbush after ET setbackMarch 1, 2025 | markets.businessinsider.comPraxis shares slump as committee says drug trial unlikely to meet main goalMarch 1, 2025 | reuters.comMarket Whales and Their Recent Bets on PRAX OptionsMarch 1, 2025 | benzinga.comPraxis Precision price target lowered to $61 from $114 at TD CowenMarch 1, 2025 | markets.businessinsider.comPraxis Precision provides corporate updates, anticipated milestonesFebruary 28, 2025 | markets.businessinsider.comPraxis Precision reports Q4 EPS ($2.94), consensus ($2.82)February 28, 2025 | markets.businessinsider.comPraxis to advance late-stage program for lead asset despite doubts over successFebruary 28, 2025 | msn.comPraxis Precision: Panel Recommends Stopping Essential Tremor Study for FutilityFebruary 28, 2025 | marketwatch.comPraxis' tremor drug trial unlikely to meet main goalFebruary 28, 2025 | msn.comPraxis Precision Medicines Shares Slide on Study SetbackFebruary 28, 2025 | marketwatch.comPraxis Precision Medicines Provides Update on Essential3 and Corporate UpdateFebruary 28, 2025 | globenewswire.comPraxis Precision Medicines (PRAX) Projected to Post Earnings on TuesdayPraxis Precision Medicines (NASDAQ:PRAX) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.5% - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 8.5% - Time to Sell?February 24, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by BrokeragesShares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) have received an average rating of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine haveFebruary 23, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Lessened by Hussman Strategic Advisors Inc.Hussman Strategic Advisors Inc. decreased its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,500 shares of the company's stock after selliFebruary 22, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 4.9% - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Trading 4.9% Higher - What's Next?February 20, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 8.6% - Here's What HappenedPraxis Precision Medicines (NASDAQ:PRAX) Trading Down 8.6% - Here's WhyFebruary 19, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Acquired by CIBC Asset Management IncCIBC Asset Management Inc raised its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 47.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 366,756 shares of the company'sFebruary 18, 2025 | marketbeat.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Sees Large Increase in Short InterestPraxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,620,000 shares, an increase of 28.4% from the January 15th total of 2,040,000 shares. Based on an average trading volume of 377,300 shares, the short-interest ratio is presently 6.9 days. Approximately 15.2% of the company's shares are sold short.February 17, 2025 | marketbeat.com Remove Ads Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address PRAX Media Mentions By Week PRAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRAX News Sentiment▼0.850.64▲Average Medical News Sentiment PRAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRAX Articles This Week▼64▲PRAX Articles Average Week Remove Ads Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Scholar Rock News Today Protagonist Therapeutics News Today Catalyst Pharmaceuticals News Today Alvotech News Today Merus News Today Immunovant News Today Metsera News Today MorphoSys News Today ACADIA Pharmaceuticals News Today Apellis Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRAX) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
